Immunocore's Participation in Major Investor Conferences
Immunocore Holdings plc (Nasdaq: IMCR) has exciting developments on the horizon as it announces participation in prestigious investor conferences this November. This biotech company, renowned for its groundbreaking immunomodulating medicines, is set to engage with investors and showcase its latest advancements in immunotherapies tailored for cancer, infectious diseases, and autoimmune disorders.
Scheduled Conference Details
The following events mark important opportunities for Immunocore to highlight its innovations:
Guggenheim 2nd Annual Healthcare Innovation Conference
Immunocore is slated for a fireside chat on Tuesday, November 11, at 3:00 p.m. EST. This conference promises to be a significant moment for the company, allowing it to delve into its pioneering research and development efforts.
Jefferies London Healthcare Conference
Following the first event, Immunocore will also participate in the Jefferies London Healthcare Conference with a fireside chat on Wednesday, November 19, at 3:30 p.m. GMT. These discussions will provide valuable insights into the company’s future directions and current therapeutic innovations.
Accessing Live Presentations
For investors interested in the latest from Immunocore, the presentations at these conferences will be available as live webcasts. Attendees will need to visit the 'Events & Presentations' section under 'Investors' on Immunocore’s official website. After each conference, a replay of the presentations will be made accessible for a limited time, allowing a broader audience to engage with the content discussed during the sessions.
About Immunocore
Immunocore is recognized for its pioneering approaches in the development of TCR bispecific immunotherapies, specifically the ImmTAX platform. This unique class of immunotherapy is designed to mobilize the immune system against various diseases such as cancer and autoimmune disorders. The company has a robust pipeline that includes active clinical and pre-clinical programs focused on diverse therapeutic areas.
Focus on KIMMTRAK
One of the flagship products, KIMMTRAK, received approval for treating HLA-A*02:01-positive adult patients suffering from unresectable or metastatic uveal melanoma. This therapy has gained recognition across various regions including the U.S., the European Union, Canada, Australia, and the U.K., indicating Immunocore's commitment to enhancing treatment outcomes for patients globally.
Company Contact Information
For further inquiries, executives at Immunocore are accessible to the public:
Immunocore
Sébastien Desprez, VP Communications
T: +44 (0) 7458030732
E: sebastien.desprez@immunocore.com
Connect with Immunocore on LinkedIn: @Immunocore
Investor Relations
For investor-related inquiries, please reach out to:
Clayton Robertson / Morgan Warenius
T: +1 (215) 384-4781
E: ir@immunocore.com
Frequently Asked Questions
What is the purpose of Immunocore's participation in these conferences?
Immunocore aims to engage with investors, providing updates on its innovative therapies and ongoing research efforts, especially in immunotherapy.
When will the presentations be available for viewing?
The live webcasts of the presentations will be accessible during the conferences, with replays available for a limited time afterward.
What is Immunocore's main therapeutic platform?
Immunocore's main platform is the ImmTAX, which focuses on developing TCR bispecific immunotherapies for treating a broad range of diseases.
What recent approvals has Immunocore achieved?
Immunocore's lead product, KIMMTRAK, has been approved for treating certain adult patients with metastatic uveal melanoma in several countries.
How can investors contact Immunocore for more information?
Investors can reach out via the contact information provided, specifically through the VP of Communications or the Investor Relations team.
